spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  botulinum toxin 

 HSMN NewsFeed - 8 Feb 2022
FDA Approves JUVÉDERM(R) VOLBELLA(R) XC for Undereye Hollows
Devices Dermatology FDA
 HSMN NewsFeed - 7 Feb 2022
Vensica Closes $19 Million Round with Investment from Strategic Partner Merz
Devices Drug Delivery Urology Venture Capital
 HSMN NewsFeed - 23 Dec 2021
Healis Therapeutics announces mission to deliver new class of neuromuscular treatments in psychiatry
Biopharmaceuticals
 HSMN NewsFeed - 1 Nov 2021
Vensica Therapeutics Closes $16 Million Investment Round
Devices Drug Delivery Urology Venture Capital
 HSMN NewsFeed - 22 Jun 2020
FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX(R) (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 18 Dec 2019
Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality(R) (galcanezumab-gnlm)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Nov 2019
Allergan(R) Announces First Annual National BOTOX(R) Cosmetic (onabotulinumtoxinA) Day
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 24 Oct 2019
FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Jun 2019
FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 May 2019
AEON Biopharma Appoints BOTOX(R) Therapeutic Head as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Mar 2019
FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Aug 2016
Ipsen Biopharmaceuticals, Inc. Announces FDA Approval of Dysport(R) (Abobotulinumtoxin A) for the Treatment of Lower Limb Spasticity in Pediatric Patients Aged Two and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Aug 2016
Ipsen Announces FDA Approval of Dysport(R) (abobotulinumtoxinA) for Injection for the Treatment of Lower Limb Spasticity in Children Aged Two and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Feb 2016
Galderma Delivers Innovation In Dermal Fillers With The Launch Of Two First-In-Class FDA Pivotal Phase III Trials
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 22 Jan 2016
U.S. FDA Approves BOTOX(R) (onabotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Sep 2015
Rosa Griffin Joins Intronix Technologies as Sales and Marketing Manager
Devices Personnel
 HSMN NewsFeed - 3 Jul 2015
Revance Therapeutics Announces Change in Role of Jacob Waugh, M.D.
Biopharmaceuticals Drug Delivery Dermatology Personnel
 HSMN NewsFeed - 15 Jan 2015
OCuSOFT(R) Introduces HypoChlor(TM) Spray and Gel (Hypochlorous Acid 0.02%) As Adjunct Therapy to its Lid Scrub(R) Family of Eyelid Cleansers
Biopharmaceuticals Ophthalmology Product Launch
 HSMN NewsFeed - 5 Nov 2014
Ipsen Biopharmaceuticals, Inc. Announces Hire of Donald Pearl as Vice President of Neurology
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 11 Jul 2014
Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe1
Biopharmaceuticals Dermatology Distribution
 HSMN NewsFeed - 1 May 2014
BOTOX(R) (Botulinum Toxin Type A) Receives a Positive Opinion in Fourteen European Countries for the Treatment of Focal Spasticity of the Ankle in Adult Post Stroke Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 Mar 2014
Revance to Add Angus C. Russell as Chairman to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Feb 2014
Ipsen announces clinical results of Dysport(R) Next Generation (DNG) and its intent to file the first ready-to-use liquid toxin A in Europe and ROW(1)
Biopharmaceuticals
 HSMN NewsFeed - 4 Feb 2014
BOTOX(R) (Botulinum toxin type A) Receives Approval in the UK for the Treatment of Ankle Disability due to Lower Limb Spasticity Associated with Stroke in Adults
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 7 Jan 2014
Allergan, Inc. and Medytox, Inc. Complete Licensing Agreement
Biopharmaceuticals Licensing
 HSMN NewsFeed - 23 Oct 2013
FDA Approves JUVÉDERM VOLUMA(TM) XC
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 9 Oct 2013
ALPHAEON to Launch the First Early Cataract Detection Device
Devices Ophthalmology Licensing Product Launch
 HSMN NewsFeed - 25 Mar 2013
Revance Therapeutics Announces Appointment of Lauren Silvernail as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jul 2012
Response Biomedical Corp. Announces New Hire, Mr. Tim Shannon, as Senior Vice President, World Wide Sales & Marketing
Diagnostics Personnel
 HSMN NewsFeed - 13 Apr 2012
BOTOX(R) Cosmetic (onabotulinumtoxinA) Celebrates 10-Year Anniversary of U.S. Food and Drug Administration Approval
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 21 Jul 2011
Merz Aesthetics Announces FDA Approval Of XEOMIN(R) (incobotulinumtoxinA) For The Temporary Improvement In The Appearance Of Moderate To Severe Glabellar Lines In Adult Patients
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 10 Jun 2011
Revance Announces $45 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 4 Jan 2011
Response Biomedical Corporation Enters Into Exclusive Italian Distribution Agreement with Cremascoli & Iris, s.r.l.
Diagnostics Distribution
 HSMN NewsFeed - 26 Oct 2010
Response Biomedical Corporation Announces the Resignation of Chief Operating Officer
Diagnostics Personnel
 HSMN NewsFeed - 13 Sep 2010
Response Biomedical Announces Strategic Realignment of Resources
Diagnostics
 HSMN NewsFeed - 26 Aug 2010
XOMA Appoints Jack L. Wyszomierski to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Aug 2010
US WorldMeds Acquires Solstice Neurosciences
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 2 Aug 2010
FDA Approves Merz Pharmaceuticals' Xeomin(R) (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 9 Jul 2010
BOTOX(R) Receives First Authorisation in UK as Preventative Treatment in Chronic Migraine
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Jun 2010
Ipsen: Encouraging results of GuidAge(R), large scale European trial conducted in the prevention of Alzheimer's Dementia
Biopharmaceuticals Neurology
 HSMN NewsFeed - 4 Jan 2010
Revance Announces Series D Financing
Biopharmaceuticals Drug Delivery Venture Capital
 HSMN NewsFeed - 17 Nov 2009
XOMA Appoints Jim Neal Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Oct 2009
Ipsen Announces the Launch of Dysport(R) (abobotulinumtoxinA) in the United States for the Treatment of Cervical Dystonia
Biopharmaceuticals
 HSMN NewsFeed - 21 Sep 2009
AZZALURE(R) approved in Spain for Aesthetic Use in the Treatment of Glabellar Lines
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 4 Aug 2009
DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jul 2009
Response Biomedical Receives U.S. FDA 510(k) Market Clearance of Rapid Respiratory Syncytial Virus Test
Diagnostics FDA
 HSMN NewsFeed - 29 Jun 2009
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Biopharmaceuticals
 HSMN NewsFeed - 26 Jun 2009
AZZALURE(R) Approved in Germany for Aesthetic Use in the Treatment of Glabellar Lines
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 30 Apr 2009
FDA Approves Dysport(TM) for Therapeutic and Aesthetic Uses
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Mar 2009
AZZALURE( )is Approved in France for Aesthetic Use in the Treatment of Frown Lines
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 13 Mar 2009
DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Mar 2009
Ipsen: AZZALURE Approved in the UK for Aesthetic Use in the Treatment of Glabellar Lines
Biopharmaceuticals Regulatory Dermatology
 HSMN NewsFeed - 2 Feb 2009
The Health Authorities of 15 European Countries Give a Collective Green Light to Azzalure For the Treatment of Glabellar Lines, Paving the Way for National Marketing Authorizations
Biopharmaceuticals Regulatory Dermatology
 HSMN NewsFeed - 6 Jan 2009
DOR BioPharma Obtains Fast Track Designation for DOR201 in the Prevention of Acute Radiation Enteritis
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2008
DOR BioPharma Forms orBec(R) European Medical Advisory Board
Biopharmaceuticals
 HSMN NewsFeed - 11 Sep 2008
Allergan Announces Positive Top-Line Results from Phase III BOTOX(R) Headache Program
Biopharmaceuticals
 HSMN NewsFeed - 22 Jul 2008
Response Biomedical Receives US FDA Clearance for RAMP(R) NT-proBNP Test for Diagnosis of Heart Failure
Diagnostics Cardiology FDA
 HSMN NewsFeed - 23 May 2008
DOR BioPharma Opens New Corporate Office in United Kingdom
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2008
DOR BioPharma Provides Update on orBec(R) European Regulatory and Development Strategy
Biopharmaceuticals
 HSMN NewsFeed - 12 May 2008
Revance Announces Series C Expansion
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 17 Apr 2008
Response Biomedical Receives U.S. FDA 510(k) Market Clearance of Rapid Influenza A+B Test
Diagnostics FDA
 HSMN NewsFeed - 8 Feb 2008
Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
Biopharmaceuticals
 HSMN NewsFeed - 31 Jan 2008
Ipsen: FDA Accepts for Filing a Biologics License Application (BLA) for Dysport(R) in Cervical Dystonia
Biopharmaceuticals
 HSMN NewsFeed - 3 Jan 2008
DOR BioPharma Receives Orphan Drug Designation for Oral BDP for the Treatment of Pediatric Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 21 Dec 2007
Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Dec 2007
DOR BioPharma Announces Results of orBec(R) End of Review Conference With the FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Dec 2007
Ipsen Grants Galderma Exclusive Rights to Promote and Distribute Dysport(R) in Aesthetic Medicine and Dermatological Indications in Brazil, Argentina and Paraguay
Biopharmaceuticals Distribution Dermatology
 HSMN NewsFeed - 14 Nov 2007
Kythera Biopharmaceuticals Appoints Industry Veteran as Vice President, Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Oct 2007
DOR BioPharma Receives Not Approvable Letter From FDA for orBec(R) for Treatment of Gastrointestinal Graft-versus-Host Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Oct 2007
Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 9 Oct 2007
orBec(R) Clinical Summary Published in "Expert Opinion on Investigational Drugs"
Biopharmaceuticals
 HSMN NewsFeed - 19 Sep 2007
Allergan, Inc. Announces Agreement to Acquire Esprit Pharma, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Sep 2007
Response Biomedical appoints S. Wayne Kay Chief Executive Officer
Diagnostics Personnel
 HSMN NewsFeed - 3 Jul 2007
Mentor Announces Initial Patient Injections in Phase III Study for PurTox(R) Botulinum Toxin Type A
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 26 Jun 2007
Allergan Announces FDA Approval of Label Extensions for JUVEDERM(TM) Ultra and JUVEDERM(TM) Ultra Plus
Devices Dermatology FDA
 HSMN NewsFeed - 12 Jun 2007
Response Biomedical Receives Approval to Market NT-proBNP Congestive Heart Failure Marker Test in Canada
Diagnostics Cardiology Regulatory
 HSMN NewsFeed - 11 Jun 2007
Response Biomedical Files for US FDA 510(k) Market Clearance of Rapid Influenza A+B Test
Diagnostics FDA
 HSMN NewsFeed - 15 May 2007
Solstice Neurosciences, Inc. Announces Commercialization Agreement
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2007
FDA Advisory Panel Reviews DOR BioPharma's orBec(R) for Treatment of GI GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Apr 2007
DOR BioPharma Announces Initiation of Clinical Development Program for Oral Leuprolide
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 20 Mar 2007
DOR BioPharma Forms orBec(R) Medical Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jan 2007
FDA Advisory Committee to Review DOR BioPharma's orBec(R) for the Treatment of GI GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Jan 2007
Allergan, Inc. Announces Nationwide Availability of JUVEDERM(TM) ULTRA and JUVEDERM(TM) ULTRA PLUS Dermal Fillers
Devices
 HSMN NewsFeed - 14 Dec 2006
Response Biomedical Files for US FDA 510k Market Clearance of RAMP NT-proBNP Test for the Diagnosis of Congestive Heart Failure
Diagnostics Cardiology FDA
 HSMN NewsFeed - 28 Nov 2006
European Medicines Agency Accepts DOR BioPharma's MAA Filing for orBec(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Nov 2006
FDA Accepts DOR BioPharma's NDA Filing for orBec(R)
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 8 Nov 2006
Deep Brain Stimulation Benefits Primary Dystonia Sufferers Says Study Published in New England Journal of Medicine
Devices Neurology
 HSMN NewsFeed - 8 Nov 2006
Solstice Neurosciences Raises $85 Million in Private Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Nov 2006
DOR BioPharma Submits European Marketing Application for orBec(R) to Treat GI Graft-Versus-Host Disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 Oct 2006
Allergan Integrates Inamed's Commercial and Research and Development Operations within New Corporate Division, Allergan Medical
Devices Mergers & Acquisitions
 HSMN NewsFeed - 26 Sep 2006
Allergan, Inc. Announces Launch of JUVEDERM(TM) ULTRA and JUVEDERM(TM) ULTRA PLUS
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 22 Sep 2006
DOR BioPharma Files New Drug Application with FDA to Market orBec for GI GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Jul 2006
Response Biomedical Completes US Distribution Network For RAMP Cardiovascular Products
Diagnostics Cardiology Distribution
 HSMN NewsFeed - 15 May 2006
Response Biomedical and Shionogi Finalize Commercialization Agreement For RAMP Cardiovascular Testing in Japan
Diagnostics Cardiology
 HSMN NewsFeed - 15 May 2006
Mentor Begins U.S. Phase 1 Study of Its Botulinum Toxin Product for Spasmodic Torticollis/Cervical Dystonia
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 53

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 53 additional stories matching:
botulinum toxin
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.